Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer

Naiqing Xu^{1

2

3}, Wenfeng Fang⁴, Libing Mu⁵, Yanna Tang⁴, Lei Gao², Shengxiang Ren⁶, Dengfeng Cao⁷, Lixin Zhou⁸, Aiqun Zhang⁹, Deruo Liu¹⁰, Caicun Zhou⁶, Kwok-Kin Wong¹¹, Lei Yu¹², Li Zhang⁴, Liang Chen^{1

2

3

13}

Affiliations

¹ Graduate School of Peking Union Medical College, Beijing, China.
² National Institute of Biological Sciences, Beijing, China.
³ Chinese Academy of Medical Sciences, Beijing, China.
⁴ Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
⁵ Tsinghua University School of Medicine, Beijing, China.
⁶ Shanghai Pulmonary Hospital, Shanghai, China.
⁷ Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, China.
⁸ Peking University Cancer Hospital, Beijing, China.
⁹ General Hospital of People's Liberation Army, Beijing, China.
¹⁰ Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China.
¹¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
¹² Beijing Tongren Hospital, Capital Medical University, Beijing, China.
¹³ National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, China.

Published Erratum

Naiqing Xu et al. Oncotarget. 2018.

. 2018 Oct 16;9(81):35284.

doi: 10.18632/oncotarget.26254.

¹ Graduate School of Peking Union Medical College, Beijing, China.
² National Institute of Biological Sciences, Beijing, China.
³ Chinese Academy of Medical Sciences, Beijing, China.
⁴ Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
⁵ Tsinghua University School of Medicine, Beijing, China.
⁶ Shanghai Pulmonary Hospital, Shanghai, China.
⁷ Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, China.
⁸ Peking University Cancer Hospital, Beijing, China.
⁹ General Hospital of People's Liberation Army, Beijing, China.
¹⁰ Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China.
¹¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
¹² Beijing Tongren Hospital, Capital Medical University, Beijing, China.
¹³ National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, China.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.6461.].

Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.
Xu N, Fang W, Mu L, Tang Y, Gao L, Ren S, Cao D, Zhou L, Zhang A, Liu D, Zhou C, Wong KK, Yu L, Zhang L, Chen L. Xu N, et al. Oncotarget. 2016 Jan 26;7(4):3884-96. doi: 10.18632/oncotarget.6461. Oncotarget. 2016. PMID: 26646697 Free PMC article.